期刊文献+

突变型K-ras siRNA抑制肺癌A549细胞的增殖和迁移并诱导细胞凋亡 被引量:1

Mutant K-ras-specific siRNA inhibits proliferation,migration and induces apoptosis of lung cancer A549 cells
下载PDF
导出
摘要 目的:构建靶向K-ras的siRNA,研究K—rassiRNA对K-ras基因突变型肺癌细胞A549及K-ras野生型小细胞肺癌细胞NCI—H446生长和迁移的抑制作用。方法:设计并人工合成4条K.rassiRNA(针对野生型K-ras基因的K—rassiRNA1-K—rassiRNA3;针对突变型K-ras基因的K—rassiRNA4),并分别转入A549和NCI—H446细胞。RT—PCR和Westernblotting检测不同K—rassiRNA对K—rasmRNA和蛋白表达的影响,MTr法检测不同K—rassiRNA对A549和NCI—H446细胞增殖的抑制作用。Transwell实验和Hoechst33258染色检测K—rassiRNA对细胞迁移和凋亡的影响。结果:靶向突变型K-ras的K.rassiR—NA4能特异性抑制A549细胞中K-ras的表达,但对N-ras和H-ras的表达没有影响。K—rassiRNA4抑制A549细胞的增殖,但不影响含野生型K-ras基因的NCI—H446细胞的增殖。K—rassiRNA4还能诱导A549细胞凋亡、抑制A549细胞迁移。结论:针对突变型K-ras基因的siRNA可特异性抑制K-ras突变型肺癌细胞的增殖和迁移,并诱导该细胞凋亡,K—rassiRNA可望用于K-ras突变型肿瘤特别是肺癌的个体化治疗。 Objective:To construct K-ras-targeted siRNAs (K-ras siRNA) and to investigate the inhibitory effects of K-ras siRNAs on the growth and migration of lung cancer A549 cells ( containing mutant K-ras gene) and NCI-H446 cells ( containing wild-type K-ras gene). Methods : Four K-ras siRNAs ( K-ras siRNA1 - K-ras siRNA3 targeting wild-type K-ras and K-ras siRNA4 targeting mutant K-ras) were designed and artificially synthesized; they were used to transfect A549 cells and NCI-H446 cells. The expressions of Ras mRNA and protein were examined by RT-PCR and Western blotting. The inhibitory effects of K-ras siRNAs on the proliferations of A549 and NCI-H446 cells were determined by MTT assay. The effects of K-ras siRNAs on the cell migration and apoptosis were observed by Transwell assay and Hoechst 33258 staining, respectively. Results: Mutant K-ras-targeted siRNA ( K-ras siRNA4) specifically inhibited the K-ras expression but had no influence on H-ras and N-ras expression in A.549 cells. K-ras siRNA4 inhibited the proliferation of A549 cells but did not inhibit that of NCI-H446 cells, which contained wild type K-ras gene. K-ras siRNA4 also induced apoptosis and inhibited migration of A549 cells. Conclusion: Mutant K-ras-targeted siRNA4 can inhibit the proliferation, migration and induce apoptosis of A549 cells. It may be a potential and personalized drug for the treatment against lung cancer containing mutant K-ras gene.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2009年第6期564-569,共6页 Chinese Journal of Cancer Biotherapy
基金 国家高技术研究发展计划(863计划)课题资助项目(No.2008AA02Z135) 福建省发改委课题资助项目(2008第3批26号)~~
关键词 肺肿瘤 RNAi K-RAS A549细胞 NCI—H446细胞 lung neoplasms: RNA interference: K-ras: A549 cell: NCI-H446 cell
  • 相关文献

参考文献24

  • 1Jemal A, Siegel R. Ward E, et al. Cancer statistics [J]. CA Cancer J Clin, 2009.59(4) : 225-249.
  • 2Herhst RS, Heymach JV, Lippman SM. Lung cancer [J]. N Engl J Med, 2008, 359(13): 1367-1380.
  • 3Clayton SJ, Scott FM, Walker J, et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification [J]. Clin Chem, 2000, 46(12) : 1929-1938.
  • 4王启钊,刁勇,许瑞安.肺癌发生机理和分子疗法[M].北京大学医学出版社.2008:433-525.
  • 5Riely GJ, Marks J, Pao W. K-ras mutations in non-small cell lung cancer[J]. Proc Am Thorac Soc. 2009, 6(2) : 201-205.
  • 6Sarturi G, Cavazza A, Sgamhato A, et al. EGFR and K-ras mutations along the spectrum of puhnonary epithelial tumors of the lung and elahoration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors [J]. AM J Clin Pathol. 2009, 131 (4) : 478-489.
  • 7Ding Li, Gelz G, Wheeler DA, et al. Somalic mutations affect key pathways in tung adenocarcinoma [J].Nature, 2008, 455(7216) : 1069-1075.
  • 8Herbst RS, Lippman SM. Molecular signatures of lung cancer- toward personalized therapy [J]. N Engl J Med, 2007, 356( 1 ) : 76-78.
  • 9Jenkins N. Methods in bioteehnology, Vol. 8 [ M ]. Totowa NJ, Humana Press Inc, 1999 : 205-222.
  • 10张志平,姜冠潮,杨帆,周足力,王俊.突变K-ras基因siRNA腺病毒载体的构建及其对人肺腺癌细胞株H441的影响[J].中国肿瘤临床,2007,34(9):481-484. 被引量:2

二级参考文献17

  • 1张峰,刘三光,刘晔,李冬斌,李荣琴,谢绍建,蔡建辉.突变体富集聚合酶链反应检测胰腺癌K-ras基因突变的研究[J].中华实验外科杂志,2005,22(8):1018-1018. 被引量:6
  • 2刘丹,陶泽璋,陈始明,肖伯奎.RNA干扰hTERT基因治疗喉鳞状细胞癌的实验研究[J].中国肿瘤临床,2005,32(20):1182-1186. 被引量:7
  • 3Qiu P, Ziegelhoffer P, Sun EC, et al. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization.Gene Therapy, 1996, 3,262-268.
  • 4Kita K, Saito S, Morioka CY, et al. Growth inhibition of human pancreatic cancer, cell lines by anti-sense oligonucleotides specific. to mutated K-ras genes. Int J Cancer, 1999, 80:553-558.
  • 5Kiaris H, Spandidos DA. Mutations of ras genes in human tumours (Review). Int J Oneol, 1995, 7:413-421.
  • 6Grunewald K, Lyons J, Frohlich A, et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer, 1989,43: 1037-1041.
  • 7Mascaux C, Iannino N, Martin B, et al. The role of RAS onco- gene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis [J]. Br J Cancer, 2005, 92(1): 131-139.
  • 8Fukuyama Y, Mitsudomi T, Sugio K, et al. K-ras and p53 muta- tions are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer[J].Br J Cancer, 1997, 75 (8): 1125-1130.
  • 9DownwardJ. RNA interference[J]. BMJ, 2004, 328(7450): 1245- 1248.
  • 10Kita K, Saito S, Morioka CY, et al. Growth inhibition on human pancreatic cancer cell lines by anti--sense oligonudeotides specific to mutated K-ras genes[J]. Int J Cancer, 1999, 80(4): 553~558.

共引文献9

同被引文献11

  • 1叶孟,林蕾,潘宏铭,方勇,吴金民.Caspase 3抑制剂抑制羟基喜树碱对人乳腺癌Bcap37细胞NF-κB的激活[J].中国病理生理杂志,2007,23(8):1508-1511. 被引量:3
  • 2Younes N,Fulton N,Tanaka R,et al.The presense of K-12 rasmutations in duodenal adenocarcinomas and the absence of rasmutations in other small bowel adenocarcinomas and carcinoid tumors[J].Cancer,1997,79(9):1804-1808.
  • 3Ma P,Magut M,Faller DV,et al.The role of Ras in T lymphocyte activation[J].Cell Signal,2002,14(10):849-859.
  • 4Suda K,Tomizawa K,Mitsudomi T.Biological and clinical significance of KRAS mutations in lung cancer:an oncogenic driver that contrasts with EGFR mutation[J].Cancer Metastasis Rev,2010,29(1):49-60.
  • 5Lozano MD,Zulueta JJ,Echeveste JI,et al.Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients:correlation with clinical outcomes[J].Oncologist,2011,16(6):877-885.
  • 6Findeiss S,Schmidtke C,Stadler PF,et al.A novel family of plasmid-transferred anti-sense ncRNAs[J].RNA Biol,2010,7(2):120-124.
  • 7Dancey JE.Agents targeting ras signaling pathway[J].Curr Pharm Des,2002,8(25):2259-2267.
  • 8Akli S,Keyomarsi K.Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy[J].Cancer Biol Ther,2003,2(4 Suppl 1):S38-S47.
  • 9Shih RS,Wong SH,Schoene NW,et al.Enhanced Gadd45 expression and delayed G2/M progression are p53-dependent in zinc-supplemented human bronchial epithelial cells[J].Exp Biol Med,2010,235(8):932-940.
  • 10刘娟,殷飞,姚树坤.细胞周期素D1、视网膜母细胞瘤样蛋白2及微小染色体维持蛋白7在肝细胞癌中的表达及对预后的意义[J].中国病理生理杂志,2011,27(2):304-309. 被引量:14

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部